Summary:
Graft-versus-host disease (GVHD) is a severe disorder and despite therapeutic efforts to decrease its distressing clinical manifestations, treatment is still not optimal. Here we report the results of studies, in which the purine analogue, fludarabine phosphate, was used in an attempt to modify and decrease GVHD after stem cell transplantation, across major histocompatibility barriers for murine leukemia. B-cell leukemia (BCL-1) bearing (BALB/c×C57BL/6) F1 mice received two cycles of fludarabine (0.8 mg/kg) for 5 days every 2 weeks, followed by 400 mg/kg cyclophosphamide i.p. Animals were then transplanted with C57BL/6 precursor cells and the development of leukemia and extent of GVHD was monitored both clinically and histopathologically. In the fludarabine-treated group, only nine of 28 (32%) mice developed leukemia, compared to 25 of 33 (76%) of control animals (P=0.0006 ). Mice treated with fludarabine-containing regimens prior to transplantation also had much less GVHD both clinically and at autopsy, while graft-versus-leukemia appeared to be augmented in the same animals.
Similar content being viewed by others
References
Sorensen JM, Vena DA, Fallavollita A et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five year follow-up report. J Clin Oncol 1997; 15: 458–465.
Foran JM, Oscier D, Orchard J et al. Pharamacokinetic study of single doses of oral fludarabine phosphate in patients with “low-grade” non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574–1579.
Johnson S, Smith AG, Loffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocyte leukemia The French Cooperative Group on CLL. Lancet 1996; 347: 1432–1438.
Ghandi V, Estey E, Keating MJ, Plunkett W . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116–124.
Ghandi V, Plunkett W, Weller S et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics in leukemia cells. J Clin Oncol 2001; 19: 2142–2152.
Yalman N, Sarper N, Devecioglu O et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr 2000; 42: 198–204.
Koller CA, Kantarjian HM, Feldman EJ et al. A phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer 1999; 86: 2246–2251.
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med 1998; 339: 1186–1193.
Borhnauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26: 119–125.
Priebe T, Platsoucas CD, Seki H et al. Purine nucleoside modulation of functions of human lymphocytes. Cell Immunol 1990; 129: 321–328.
Chun HG, Leyland-Jones B, Cheson BD . Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175–188.
Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.
Petrus MJ, Williams JF, Eckhaus MA et al. An immuno-ablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000; 6: 182–189.
Goodman ER, Fiedor PS, Fein S et al. Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg 1996; 62: 435–442.
Or R, Weiss L, Amir G et al. The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models. Bone Marrow Transplant 2000; 25: 263–266.
Slavin S, Strober S . Spontaneous murine B-cell leukemia. Nature 1978; 272: 624–626.
Briz M, Cabrera R, Sanjuan I et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukemia. Br J Haematol 1995; 91: 409–411.
Wijermans PW, Gerrits WB, Haak HL . Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292–296.
Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.
Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem-cell transplantation. New Engl J Med 2000; 343: 750–758.
Wasch R, Reisser S, Hahn J et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243–250.
Luznik L, Jalla S, Engstrom LW et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001; 98: 3456–3464.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weiss, L., Abdul-Hai, A., Or, R. et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia. Bone Marrow Transplant 31, 11–15 (2003). https://doi.org/10.1038/sj.bmt.1703775
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703775
- Springer Nature Limited
Keywords
This article is cited by
-
Fludarabine as a cost-effective adjuvant to enhance engraftment of human normal and malignant hematopoiesis in immunodeficient mice
Scientific Reports (2018)
-
Comparable outcomes between younger (⩽40 years) and older (>40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning
Bone Marrow Transplantation (2016)
-
Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease
Bone Marrow Transplantation (2005)